1. Home
  2. AKBA vs GSM Comparison

AKBA vs GSM Comparison

Compare AKBA & GSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • GSM
  • Stock Information
  • Founded
  • AKBA 2007
  • GSM 2015
  • Country
  • AKBA United States
  • GSM United Kingdom
  • Employees
  • AKBA N/A
  • GSM N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • GSM Metal Mining
  • Sector
  • AKBA Health Care
  • GSM Basic Materials
  • Exchange
  • AKBA Nasdaq
  • GSM Nasdaq
  • Market Cap
  • AKBA 861.7M
  • GSM 780.1M
  • IPO Year
  • AKBA 2014
  • GSM N/A
  • Fundamental
  • Price
  • AKBA $2.82
  • GSM $4.13
  • Analyst Decision
  • AKBA Strong Buy
  • GSM Hold
  • Analyst Count
  • AKBA 5
  • GSM 1
  • Target Price
  • AKBA $6.90
  • GSM N/A
  • AVG Volume (30 Days)
  • AKBA 3.6M
  • GSM 714.0K
  • Earning Date
  • AKBA 11-06-2025
  • GSM 11-05-2025
  • Dividend Yield
  • AKBA N/A
  • GSM 1.35%
  • EPS Growth
  • AKBA N/A
  • GSM N/A
  • EPS
  • AKBA N/A
  • GSM N/A
  • Revenue
  • AKBA $203,733,000.00
  • GSM $1,495,078,000.00
  • Revenue This Year
  • AKBA $43.91
  • GSM N/A
  • Revenue Next Year
  • AKBA $32.09
  • GSM $18.61
  • P/E Ratio
  • AKBA N/A
  • GSM N/A
  • Revenue Growth
  • AKBA 16.75
  • GSM N/A
  • 52 Week Low
  • AKBA $1.24
  • GSM $2.97
  • 52 Week High
  • AKBA $4.08
  • GSM $5.12
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 34.99
  • GSM 45.47
  • Support Level
  • AKBA $2.91
  • GSM $4.11
  • Resistance Level
  • AKBA $3.02
  • GSM $4.29
  • Average True Range (ATR)
  • AKBA 0.13
  • GSM 0.13
  • MACD
  • AKBA -0.01
  • GSM -0.01
  • Stochastic Oscillator
  • AKBA 0.00
  • GSM 16.67

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About GSM Ferroglobe PLC

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.

Share on Social Networks: